Dry powder inhaler and system for drug delivery
First Claim
1. A drug delivery system comprising an inhaler, a powder container, comprising fumaryl diketopiperazine (FDKP) microparticles comprising a trans-FDKP isomer content of about 45% to about 65% and a drug, wherein the aerodynamic performance of the microparticles is improved as compared to fumaryl diketopiperazine microparticles having a trans isomer content outside of said trans isomer content of about 45% to about 65%;
- andwherein in use about 10% to 70% of an air flow exiting the inhaler and entering a user passes through the powder container and about 90% to 30% of said air flow bypasses the powder container.
5 Assignments
0 Petitions
Accused Products
Abstract
A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.
-
Citations
18 Claims
-
1. A drug delivery system comprising an inhaler, a powder container, comprising fumaryl diketopiperazine (FDKP) microparticles comprising a trans-FDKP isomer content of about 45% to about 65% and a drug, wherein the aerodynamic performance of the microparticles is improved as compared to fumaryl diketopiperazine microparticles having a trans isomer content outside of said trans isomer content of about 45% to about 65%;
- and
wherein in use about 10% to 70% of an air flow exiting the inhaler and entering a user passes through the powder container and about 90% to 30% of said air flow bypasses the powder container. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 13, 14, 15, 16, 17, 18)
- and
-
9. A drug delivery system comprising an inhaler, a powder container comprising FDKP microparticles having improved aerodynamic performance that have been prepared by a process comprising determining the trans-FDKP isomer content;
-
wherein the microparticles have a trans-FDKP isomer content of about 45% to about 65% and the aerodynamic performance of the microparticles is improved as compared to fumaryl diketopiperazine microparticles having a trans isomer content outside of said trans isomer content of about 45% to about 65%; and wherein in use about 10% to 70% of an air flow exiting the inhaler and entering a user passes through the powder container and about 90% to 30% of said air flow bypasses the powder container. - View Dependent Claims (10, 11, 12)
-
Specification